Novo Nordisk A/S NVO shares are trading higher by 7.57% to $114.49 after the company reported third-quarter EPS and sales results were higher year-over-year. The company also raised FY22 operating profit growth guidance.
Novo Nordisk reported quarterly earnings of DKK6.34 per share. The company reported DKK45.57 billion in sales this quarter. This is a 28% increase over sales of DKK35.62 billion in the same period last year.
For the 2022 outlook, the company says sales growth is now expected to be 14-17% at CER and operating profit growth is now expected to be 13-16% at CER.
Sales and operating profit growth reported in Danish kroner are now expected to be 10 and 15 percentage points higher than at CER, respectively.
See Also: What's Going On With Tesla Stock Today
According to data from Benzinga Pro, Novo Nordisk A/S has a 52-week high of $122.16 and a 52-week low of $91.51.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.